Who
Simrat Randhawa
EVP, Head of R&D
Company insider
Files Form 4 as: EVP, Head of R&D, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 80
- Buys
- 2
- Sells
- 5
- Bought
- $53K
- Sold
- $22.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Sep 2023
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $134K7,500 at $17.88 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $136K6,249 at $21.77 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $207K9,375 at $22.07 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,249 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $273K2,600 at $105.19 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $767K7,215 at $106.25 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M13,309 at $106.74 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,249 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $134K7,500 at $17.88 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $136K6,249 at $21.77 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $207K9,375 at $22.07 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $273K2,600 at $105.19 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $767K7,215 at $106.25 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M13,309 at $106.74 | filing |
| 1 Jun 2026filed 2 Jun 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $34K3,998 at $8.44 | filing |
| 1 Jun 2026filed 2 Jun 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,249 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Simrat Randhawa; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.